FI945248A0 - Tat-peräisiä kuljetuspolypeptideja - Google Patents

Tat-peräisiä kuljetuspolypeptideja

Info

Publication number
FI945248A0
FI945248A0 FI945248A FI945248A FI945248A0 FI 945248 A0 FI945248 A0 FI 945248A0 FI 945248 A FI945248 A FI 945248A FI 945248 A FI945248 A FI 945248A FI 945248 A0 FI945248 A0 FI 945248A0
Authority
FI
Finland
Prior art keywords
tat
transport polypeptides
polypeptides
absence
amino acids
Prior art date
Application number
FI945248A
Other languages
English (en)
Swedish (sv)
Other versions
FI945248A (fi
FI120495B (fi
Inventor
James G Barsoum
Stephen E Fawell
R Blake Pepinsky
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of FI945248A0 publication Critical patent/FI945248A0/fi
Publication of FI945248A publication Critical patent/FI945248A/fi
Application granted granted Critical
Publication of FI120495B publication Critical patent/FI120495B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI945248A 1992-08-21 1994-11-08 Tat-peräisiä kuljetuspolypeptidejä FI120495B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93437592A 1992-08-21 1992-08-21
US93437592 1992-08-21
PCT/US1993/007833 WO1994004686A1 (en) 1992-08-21 1993-08-19 Tat-derived transport polypeptides
US9307833 1993-08-19

Publications (3)

Publication Number Publication Date
FI945248A0 true FI945248A0 (fi) 1994-11-08
FI945248A FI945248A (fi) 1995-01-05
FI120495B FI120495B (fi) 2009-11-13

Family

ID=25465458

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945248A FI120495B (fi) 1992-08-21 1994-11-08 Tat-peräisiä kuljetuspolypeptidejä

Country Status (14)

Country Link
EP (3) EP0656950B1 (fi)
JP (2) JP2702285B2 (fi)
KR (1) KR0153027B1 (fi)
AT (1) ATE173016T1 (fi)
AU (1) AU667244B2 (fi)
CA (1) CA2135642C (fi)
DE (2) DE69321962T2 (fi)
DK (1) DK0656950T3 (fi)
ES (1) ES2123062T3 (fi)
FI (1) FI120495B (fi)
HK (1) HK1012678A1 (fi)
NO (1) NO316761B1 (fi)
NZ (1) NZ255831A (fi)
WO (1) WO1994004686A1 (fi)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219990A (en) * 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5955593A (en) * 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
EP0972025A1 (en) 1997-01-21 2000-01-19 Human Genome Sciences, Inc. I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis
CA2291074C (en) 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
CA2291483C (en) 1997-06-06 2012-09-18 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7306784B2 (en) 1998-06-20 2007-12-11 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
US6348185B1 (en) 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
WO2000038733A1 (en) * 1998-12-24 2000-07-06 Ucb S.A. Peptidic product, process and composition
DE19916224C1 (de) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6881825B1 (en) 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2396149A1 (en) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
AU8466501A (en) 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
KR100379577B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법
KR100379578B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티-씨3 트랜스페라제 융합단백질, 이융합단백질의 발현벡터 및 티에이티-씨3 트랜스페라제를이용한 로 단백질의 생리적 기능 분석방법
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
ATE437647T1 (de) 2001-02-16 2009-08-15 Cellgate Inc Transporter mit beabstandeten arginin-teilchen
CA2449802C (en) 2001-06-05 2012-02-07 Pola Chemical Industries Inc. Polypeptide for unstabilizing a protein in a cell under aerobic conditions and dna encoding the same
KR100495138B1 (ko) * 2001-07-31 2005-06-14 학교법인 한림대학교 식물세포 투과 도메인-화물분자 복합체
EP1427856B1 (en) 2001-09-18 2011-05-11 Carnegie Institution Of Washington Fusion proteins useful for detecting analytes
WO2003035892A2 (en) * 2001-10-19 2003-05-01 The Scripps Research Institute Novel methods for introducing molecules into cells and vectors and compositions for use in such methods
CA2471762C (en) 2002-01-09 2010-08-17 University Of Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US7026166B2 (en) 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
WO2003086470A2 (en) * 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354953A1 (en) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
CA2482598C (en) 2002-04-22 2012-09-25 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
KR100472939B1 (ko) * 2002-05-24 2005-03-18 학교법인 한림대학교 세포침투성 티에이티-피리독살 카이네이즈 융합단백질 및그 용도
WO2004009665A2 (en) 2002-07-19 2004-01-29 The Regents Of The University Of California Dendrimers as molecular translocators
KR100472938B1 (ko) * 2002-10-31 2005-03-11 학교법인 한림대학교 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
DK2351844T3 (da) 2003-04-29 2014-09-22 Sarepta Therapeutics Inc Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler
WO2005035562A1 (ja) * 2003-10-07 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 新規な細胞増殖促進剤
ES2324538T3 (es) 2003-12-05 2009-08-10 Multimmune Gmbh Anticuerpos anti-hsp terapeuticos y de diagnostico.
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150570A1 (en) 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
JP4474264B2 (ja) * 2004-08-20 2010-06-02 生寶生物科技股▲ふん▼有限公司 子宮頸癌抑制の融合蛋白
EP1793847A2 (en) 2004-09-21 2007-06-13 NascaCell IP GmbH Use of microproteins as tryptase inhibitors
JP4596391B2 (ja) 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
DK1988167T3 (da) * 2005-02-17 2020-07-13 Univ Sorbonne Intracellulære inhiberende peptider
CN102499981B (zh) 2005-03-03 2016-08-03 雷文斯治疗公司 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法
ZA200707351B (en) 2005-03-03 2010-02-24 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
EP1861417B1 (en) 2005-03-10 2013-05-15 BioNTech AG Dimeric or multimeric microproteins
KR100699279B1 (ko) 2005-04-28 2007-03-23 학교법인 포항공과대학교 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법
US7973084B2 (en) 2005-04-28 2011-07-05 Postech Academy-Industrial Foundation Molecular transporters based on alditol or inositol and processes for the preparation thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
US7517959B2 (en) 2005-11-11 2009-04-14 Walter And Eliza Hall Institute Of Medical Research SOCS3 proteins
SG177954A1 (en) 2007-01-05 2012-02-28 Univ Zuerich Method of providing disease-specific binding molecules and targets
PT2457928T (pt) 2007-03-13 2017-08-17 Univ Zuerich Anticorpo monoclonal humano específico de tumores
AU2008224950B2 (en) 2007-03-13 2013-10-03 National Jewish Medical And Research Center Methods for generation of antibodies
US20110038865A1 (en) 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CA2694046C (en) 2007-07-26 2023-09-12 Revance Therapeutics, Inc. Cationic peptides and compositions thereof
WO2009033743A1 (en) 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US7935816B2 (en) 2007-10-25 2011-05-03 Gene Tools, Llc Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
KR101585046B1 (ko) 2008-02-28 2016-01-13 도레이 카부시키가이샤 경비 투여용 의약 조성물
KR101803099B1 (ko) 2008-05-16 2017-11-30 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
ES2525411T3 (es) 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
CA2735710A1 (en) 2008-08-04 2010-02-11 Glen N. Barber Sting (stimulator of interferon genes), a regulator of innate immune responses
JP5812861B2 (ja) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
BRPI1008230B1 (pt) 2009-05-20 2019-05-28 Toray Industries, Inc. Peptídeo de penetração celular e composição farmacêutica
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CN105457016B (zh) 2010-09-22 2022-06-24 科罗拉多大学董事会 Smad7的治疗应用
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
PT2663580T (pt) 2011-01-10 2017-03-10 Univ Zuerich Terapêutica de associação incluindo anticorpos de ligação a antigénios associados a tumores
EP2704749A1 (en) 2011-05-05 2014-03-12 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2012163769A1 (en) 2011-06-03 2012-12-06 Ct Atlantic Ltd. Magea3 binding antibodies
WO2012163771A1 (en) 2011-06-03 2012-12-06 Ct Atlantic Ltd. Magea3 binding antibodies
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
CA2861793C (en) 2011-12-28 2023-08-01 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
EP3868387A1 (en) 2012-07-20 2021-08-25 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
WO2014138670A1 (en) 2013-03-08 2014-09-12 The Regents Of The University Of Colorado, A Body Corporate Ptd-smad7 therapeutics
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
AU2014249045A1 (en) 2013-03-11 2015-10-29 University Of Florida Research Foundation, Inc. Delivery of CARD protein as therapy for occular inflammation
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
US10624948B2 (en) 2013-06-26 2020-04-21 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US10112995B2 (en) 2013-07-03 2018-10-30 Immunoqure Ag Human anti-IFN-α antibodies
AU2015229381B2 (en) 2014-03-11 2019-11-07 University Of Florida Research Foundation, Inc. Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic
JP6468722B2 (ja) * 2014-04-30 2019-02-13 日本信号株式会社 物体検出装置
CA2987877A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T-cell receptor specific antibodies
WO2016193299A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T cell receptor library
AU2016273214B2 (en) 2015-06-01 2018-10-18 Medigene Immunotherapies Gmbh Method for generating antibodies against T cell receptor
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
JP6864364B2 (ja) 2015-06-11 2021-04-28 学校法人慶應義塾 融合タンパク質又は複合タンパク質、細胞内送達用担体、部分ペプチド、細胞膜透過促進剤、ｄｎａ、及びベクター
DK3394247T3 (da) 2015-12-23 2021-04-12 Medigene Immunotherapies Gmbh Ny generering af antigen-specifikke tcr'er
WO2018102678A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
KR102552428B1 (ko) 2016-12-19 2023-07-06 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
JP7489319B2 (ja) 2018-09-26 2024-05-23 株式会社カネカ 細胞膜透過性ペプチド
JPWO2022154079A1 (fi) * 2021-01-18 2022-07-21

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658818B2 (en) * 1989-12-21 1995-05-04 Johns Hopkins University School Of Medicine, The Method of delivering molecules into eukaryotic cells using tat protein conjugate
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors

Also Published As

Publication number Publication date
EP0903408A3 (en) 2005-11-02
NO944273L (no) 1995-02-17
EP0656950B1 (en) 1998-11-04
DE69321962T2 (de) 1999-07-01
FI945248A (fi) 1995-01-05
NO944273D0 (no) 1994-11-09
EP0903408A2 (en) 1999-03-24
EP2000536A3 (en) 2010-06-30
DK0656950T3 (da) 1999-07-19
DE656950T1 (de) 1996-03-14
AU5083293A (en) 1994-03-15
NZ255831A (en) 1997-04-24
DE69321962D1 (de) 1998-12-10
KR0153027B1 (en) 1998-10-15
JPH1033186A (ja) 1998-02-10
WO1994004686A1 (en) 1994-03-03
FI120495B (fi) 2009-11-13
CA2135642A1 (en) 1994-03-03
ES2123062T3 (es) 1999-01-01
EP0656950A1 (en) 1995-06-14
NO316761B1 (no) 2004-05-03
ATE173016T1 (de) 1998-11-15
EP2000536A2 (en) 2008-12-10
AU667244B2 (en) 1996-03-14
JP2869396B2 (ja) 1999-03-10
CA2135642C (en) 1999-12-14
JP2702285B2 (ja) 1998-01-21
JPH07503617A (ja) 1995-04-20
HK1012678A1 (en) 1999-08-06

Similar Documents

Publication Publication Date Title
DK0656950T3 (da) TAT-afledte transportpolypeptider
GB9720054D0 (en) Biological products
IL128727A0 (en) Angiogenic factor and use thereof in treating cardiovascular disease
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
DE69033040D1 (de) Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
FI913637A0 (fi) Foer epitelceller specifik dna kodande vaextfaktor.
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
DE69805772T2 (de) Stabilisierte mischung auf fibrinogenbasis
NO20012017D0 (no) Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose
DE69132545D1 (de) Protein mit Cytokinaktivität, Rekombinant-DNS, Expressionsvektor und Wirtszellen zu seiner Herstellung
Burzynski et al. Biological active peptides in human urine: III. Inhibitors of the growth of human leukemia, osteosarcoma, and HeLa cells
DE60042220D1 (de) Verwendung vom transportergen oatp-c zur screening von testsubstanzen
DE3273606D1 (en) Process for the purification or concentration of biologically active proteins, and appropriate means therefor
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
ATE205538T1 (de) Genregulatorische sequenzen von cd4, welche spezifisch in reifen t-zellen exprimiert werden
ATE277176T1 (de) Faltende proteine
許奎晶 Small GTP-binding Proteins
Perraudin et al. Disulfide content of reduced hen egg white and human milk lysozymes during the folding process
KR950023648A (ko) 생물학적 활성을 나타내는 폴리펩티드
MIRZA jllafiter of $ l| ilofl (oplip
PT97820A (pt) Processo de obtencao de proteina map2-quinases, de microorganismos e linhas de celulas compreendendo moleculas recombinantes de map2-quinase e de detencao da presenca de actividade de factores celulares
TH23717A (th) ธรอมโบพอยเอติน

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ALLIBERT EQUIPEMENT

FD Application lapsed
PC Transfer of assignment of patent

Owner name: BIOGEN IDEC MA INC.

Free format text: BIOGEN IDEC MA INC.

FG Patent granted

Ref document number: 120495

Country of ref document: FI

MA Patent expired